| 1 |
NCT03474094 |
Recruiting |
Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy |
|
- Combination Product: Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery
- Combination Product: 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy
- Combination Product: Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.
|
Interventional
|
Phase 2 |
- Centre Leon Berard
- Roche Pharma AG
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathological impact of PD-L1 neutralisation (by atezolizumab) with or without radiotherapy versus radiotherapy alone in operable localised STS
- Rate of patients with complete or near-complete pathologic response
- Rate of patients with at least 50% of necrosis
- (and 12 more...)
|
69 |
All |
18 Years and older (Adult, Older Adult) |
NCT03474094 |
RT-Immune (ET16-132) |
RT-Immune |
August 1, 2018 |
July 31, 2020 |
July 31, 2021 |
March 22, 2018 |
September 28, 2018 |
|
- Centre Léon Bérard
Lyon, France - Institut Claudius Regaud
Toulouse, France - Institut Gustave Roussy
Villejuif, France
|
|
| 2 |
NCT03629002 |
Not yet recruiting |
BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA |
|
- Biological: Study of the gene expression profile
|
Observational
|
|
- Assistance Publique Hopitaux De Marseille
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Study of the gene expression profile
- Phenotypic analysis of the cells composing the stromal vascular fraction
- Cell culture of the stromal vascular fraction to isolate and expand two populations of interest
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03629002 |
2018-06
IDRCB |
sclerabio |
September 2018 |
March 2020 |
September 2020 |
August 14, 2018 |
August 14, 2018 |
|
- Direction de la Recherche Clinique et Innovation
Marseille, France
|
|
| 3 |
NCT03276442 |
Recruiting |
Biorhythms in Metabolic Tissues |
- Sleep Deprivation
- Metabolic Disturbance
- Biological Clocks
- Healthy
|
- Other: Low-fat dietary intervention
- Other: High-fat dietary intervention
|
Interventional
|
Not Applicable |
- Uppsala University
- The Swedish Research Council
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Changes in clock gene & associated omic circadian rhythms
- Wakefulness-induced changes and subsequent recovery at omic levels
- 24-h rhythms in blood
- (and 6 more...)
|
12 |
All |
18 Years to 32 Years (Adult) |
NCT03276442 |
CircHFJC2017 |
|
August 31, 2017 |
November 30, 2019 |
December 31, 2019 |
September 8, 2017 |
October 12, 2017 |
|
- Department of Neuroscience, Uppsala University
Uppsala, Sweden
|
|
| 4 |
NCT02383537 |
Not yet recruiting |
Biological Changes in the Adipose Tissue Among Pregnant Women With Diabetes |
|
|
Observational
|
|
- Hadassah Medical Organization
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
150 |
Female |
18 Years to 45 Years (Adult) |
NCT02383537 |
0633-14-HMO |
|
April 2017 |
February 2019 |
February 2020 |
March 9, 2015 |
September 2, 2016 |
|
|
|
| 5 |
NCT01129297 |
Recruiting |
A Biological Atlas of Severe Obesity (Biological Tissue Collection) |
- Obesity
- Glucose Intolerance
- Diabetes
|
|
Observational
|
|
- University Hospital, Lille
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Study the influence of phenotypic characteristics on gene expression of tissues involved in glucose metabolism
- Correlation between gene expression and tissue insulin resistance index (HOMA2) (The Homeostasis Model Assessment)
- Prospective assessment of clinical and biological features before and after bariatric surgery
- (and 2 more...)
|
20000 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01129297 |
2006_0620
DGS 2006/0307 |
ABOS |
June 2006 |
January 2025 |
January 2025 |
May 24, 2010 |
October 15, 2018 |
|
- Lille University Hospital
Lille, Nord, France
|
|
| 6 |
NCT02256241 |
Recruiting |
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin |
- Group 1: Trauma Operation for Otherwise Healthy Patients
- Group 2: Primary Tumors of Mesenchymal Origin
|
|
Observational
|
|
- Rambam Health Care Campus
- Technion, Israel Institute of Technology
|
Other |
- Observational Model: Cohort
|
- Protein and mRNA levels of RING ubiquitin ligases during osteogenesis
- Protein and mRNA levels of RING ubiquitin ligases in musculoskeletal tumors and its correlation to staging and grading
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT02256241 |
0180-14-RMB |
RING UB LIGASE |
October 2014 |
July 2019 |
July 2019 |
October 3, 2014 |
February 24, 2015 |
|
|
|
| 7 |
NCT02917759 |
Recruiting |
Liver and Biliary Tumor Tissue Registry |
- Hepatocellular Carcinoma
- Cholangiocarcinoma
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of successful xenografts established
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02917759 |
13-006829 |
|
February 2014 |
February 2024 |
February 2024 |
September 28, 2016 |
December 7, 2018 |
|
- Mayo Clinic
Jacksonville, Florida, United States
|
|
| 8 |
NCT03460132 |
Not yet recruiting |
Biological Effects of Commercial Orthodontic Miniscrews |
|
- Device: Tomas® Anchorage System - DENTAURUM
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- cytotoxicity of orthodontic miniscrew implant
- Metal release of orthodontic miniscrew implant
- surface changes of orthodontic miniscrew implants
|
10 |
Female |
14 Years to 18 Years (Child, Adult) |
NCT03460132 |
Al-Azhar 201 |
|
May 1, 2018 |
March 1, 2019 |
April 1, 2019 |
March 9, 2018 |
March 9, 2018 |
|
|
|
| 9 |
NCT03321942 |
Recruiting |
Treatment of Chronic Renal Failure With Adipose Tissue-derived Mesenchymal Stem Cells |
- Mesenchymal Stem Cells
- Chronic Kidney Diseases
- Renal Interstitial Fibrosis
|
- Drug: Treatment group
- Drug: Control group
|
Interventional
|
Not Applicable |
- The Affiliated Hospital of Xuzhou Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- serum creatinine
- glomerular filtration rate
- apparent relaxation rate
|
100 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03321942 |
XYFY2016-KL031-01 |
|
January 1, 2017 |
December 31, 2018 |
December 31, 2018 |
October 26, 2017 |
October 26, 2017 |
|
- The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
|
|
| 10 |
NCT02927392 |
Recruiting |
Brown Adipose Tissue Activity in Pre- and Postmenopausal Women |
|
|
Interventional
|
Not Applicable |
- University of Colorado, Denver
- University of Ottawa
- Université de Sherbrooke
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Brown Adipose Tissue Volume
- Brown Adipose Tissue Activity -Warm Exposure
- Brown Adipose Tissue Activity - ColdExposure
- (and 2 more...)
|
72 |
Female |
18 Years to 99 Years (Adult, Older Adult) |
NCT02927392 |
16-1479
1R01DK112260-01 |
|
January 2017 |
August 2019 |
August 2019 |
October 7, 2016 |
July 26, 2018 |
|
- University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
|
|
| 11 |
NCT00904241 |
Recruiting |
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma |
- Ganglioneuroblastoma
- Localized Resectable Neuroblastoma
- Localized Unresectable Neuroblastoma
- (and 3 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
|
- Factors currently used for risk-group assignment (DNA content, MYCN copy number, and tumor histology)
- Prevalence of 1p, 11q, 14q, and 17q allelic status
- MYCN copy number by quantitative PCR
- (and 8 more...)
|
10000 |
All |
up to 30 Years (Child, Adult) |
NCT00904241 |
ANBL00B1
NCI-2009-00397
CDR0000078642
U10CA180886
U10CA098543
UG1CA189958 |
|
November 6, 2000 |
January 1, 2100 |
|
May 19, 2009 |
August 7, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - (and 256 more...)
|
|
| 12 |
NCT01354002 |
Recruiting |
Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility |
- Normal and Diseased Tissue and Body Fluids Samples
|
|
Observational
|
|
- St. Jude Children's Research Hospital
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Collecting, processing and archiving human tissue
|
100000 |
All |
Child, Adult, Older Adult |
NCT01354002 |
TBANK |
|
September 1, 2009 |
December 2030 |
December 2030 |
May 16, 2011 |
January 11, 2019 |
|
- Huntsville Hospital for Women & Children
Huntsville, Alabama, United States - Rady Children's Hospital and Health Center
San Diego, California, United States - Children's Hospital of Illinois at OSF-Saint Francis Medical Center
Peoria, Illinois, United States - (and 8 more...)
|
|
| 13 |
NCT02469207 |
Recruiting |
Regenerative Cellular Therapies, Physiology, Pathology and Developmental Biology |
- Graft Rejection
- Transplantation
- Diabetes Mellitus
|
- Other: Removal of tissue post-mortem
|
Observational
|
|
- Cambridge University Hospitals NHS Foundation Trust
- University of Cambridge
- Cambridge Stem Cell Institute, Cambridge
- (and 5 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of donors from which induced Pluripotent Stem Cells were generated
- Number of stem cell lines for which the immune response was characterised
- Number of immunomodulatory therapies characterised
- Levels of baseline and stimulated gut hormones detected
|
50 |
All |
16 Years to 92 Years (Child, Adult, Older Adult) |
NCT02469207 |
A093532
15/EE/0152 |
RCT |
January 2016 |
June 2020 |
June 2020 |
June 11, 2015 |
July 14, 2016 |
|
- Addenbrooke's Hospital
Cambridge, United Kingdom
|
|
| 14 |
NCT00001582 |
Recruiting |
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer |
- T-cell Lymphoma
- B-Cell Lymphoma
- ATL
- Myeloma
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
1000 |
All |
1 Year to 99 Years (Child, Adult, Older Adult) |
NCT00001582 |
970143
97-C-0143 |
|
December 11, 1997 |
|
|
November 4, 1999 |
February 15, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 15 |
NCT03387865 |
Not yet recruiting |
A Clinico-biological Database of Lung Cancers |
|
- Procedure: tissue biopsies
- Procedure: blood sampling
- Genetic: DNA banking
|
Observational
|
|
- University Hospital, Lille
- Institut Pasteur de Lille
- University of Lille Nord de France
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Objective response rate assessed by CT scan
- Disease progression rate assessed by CT scan
- Progression-free survival
- (and 2 more...)
|
500 |
All |
Child, Adult, Older Adult |
NCT03387865 |
2015_43
2016-A01383-48 |
Bio-lung |
May 2019 |
March 2022 |
March 2022 |
January 2, 2018 |
September 21, 2018 |
|
|
|
| 16 |
NCT02663388 |
Recruiting |
Epigenetic Mechanisms and Severe Obesity (Biological Tissue Collection) |
- Obesity
- Diabetes
- Metabolic Diseases
- Non-alcoholic Fatty Liver Disease
|
- Procedure: gastric bypass, sleeve, gastric banding
|
Observational
|
|
- University of Lorraine
- Central Hospital, Nancy, France
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluation of folate mediated one-carbon metabolic pathway parameters (Folates, Vitamin B12, Methionine, Homocysteine) on severe obesity-related complications before and after bariatric surgery
- Evaluation of DNA Methylation on severe obesity-related complications before and after bariatric surgery
|
20000 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02663388 |
2015-A01175-44 |
OBESEPI |
January 2016 |
January 2026 |
January 2026 |
January 26, 2016 |
October 27, 2016 |
|
- University of Lorraine, CHU Nancy
Vandoeuvre Les Nancy, France
|
|
| 17 |
NCT03346317 |
Recruiting |
Comparing the Efficacy of Two Methods in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis |
|
- Device: disposable balloon uterine stent
- Procedure: dried biological amnion graft
- Drug: estradiol valerate tablets+dydrogesterone tablets
|
Interventional
|
Not Applicable |
- Beijing Obstetrics and Gynecology Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Incidence of adhesion information
- Menstruation pattern
- The change of AFS score
|
100 |
Female |
20 Years to 40 Years (Adult) |
NCT03346317 |
No.5-20171111 |
|
November 16, 2017 |
May 16, 2018 |
May 20, 2018 |
November 17, 2017 |
November 20, 2017 |
|
- Beijing Obstetrics and Gynecology Hospital，Capital Medical University
Beijing, Beijing, China
|
|
| 18 |
NCT03329898 |
Recruiting |
Comparing the Efficacy of Two Methods for the Therapy of Uterine Adhesion |
|
- Procedure: dried biological amnion graft
- Device: disposable balloon uterine stent
- Drug: estradiol valerate tablets
- Drug: dydrogesterone Tablets
|
Interventional
|
Not Applicable |
- Beijing Obstetrics and Gynecology Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- second diagnostic hysteroscopy
- pregnancy
- Menstruation Pattern
- adhesion reformation
|
200 |
Female |
20 Years to 45 Years (Adult) |
NCT03329898 |
No.4-20171020 |
|
October 31, 2017 |
October 25, 2018 |
November 25, 2018 |
November 6, 2017 |
November 17, 2017 |
|
- Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, China
|
|
| 19 |
NCT03351205 |
Recruiting |
The Efficacy of Estrogen Therapy Against Adhesion Reformation After Hysteroscopic Adhesiolysis |
|
- Device: disposable balloon uterine stent
- Procedure: dried biological amnion graft
- Drug: estradiol valerate tablets+dydrogesterone tablets
|
Interventional
|
Not Applicable |
- Beijing Obstetrics and Gynecology Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Incidence of adhesion information
- Menstruation Pattern
- The change of AFS score
|
100 |
Female |
20 Years to 40 Years (Adult) |
NCT03351205 |
No.6-20171120 |
|
November 21, 2017 |
November 21, 2018 |
November 22, 2018 |
November 22, 2017 |
November 22, 2017 |
|
- Beijing Obstetrics and Gynecology Hospital，Capital Medical University
Beijing, China
|
|
| 20 |
NCT02021279 |
Recruiting |
ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study |
|
- Device: MatriStem Pelvic Floor Matrix
- Procedure: native tissue repair
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The safety and effectiveness of surgical success/failure.
- The surgical success/failure based on an alternate definition of success.
|
162 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02021279 |
ACL2012-001 |
|
June 2014 |
January 2020 |
|
December 27, 2013 |
October 24, 2016 |
|
- Stanford School of Medicine
Stanford, California, United States - Cleveland Clinic FLorida
Weston, Florida, United States - Female Pelvic Medicine & Urogynecology
Grand Rapids, Michigan, United States - (and 10 more...)
|
|
| 21 |
NCT02270957 |
Recruiting |
Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches |
- Systemic Lupus Erythematosus
|
- Biological: Abatacept
- Other: Placebo
|
Interventional
|
Phase 2 |
- Oklahoma Medical Research Foundation
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- BILAG-based Combined Lupus Assessment (BICLA)
- BICLA and SRI at each month
- Mean SLEDAI at baseline vs 6 months
- (and 3 more...)
|
60 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02270957 |
OMRF 13-38 |
ABC |
January 2014 |
December 2018 |
December 2019 |
October 22, 2014 |
December 7, 2017 |
|
- Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States
|
|
| 22 |
NCT01676805 |
Recruiting |
Tissue Collection for Studies of Lymph Cancer |
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- (and 2 more...)
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
600 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT01676805 |
120193
12-C-0193 |
|
September 21, 2012 |
|
|
August 31, 2012 |
February 21, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 23 |
NCT03225872 |
Recruiting |
Biology of Osteosarcoma (BOOST) Registry and Biobank |
|
|
Observational
|
|
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Observational Model: Family-Based
- Time Perspective: Retrospective
|
- Determine if genes can determine osteosarcoma
|
5000 |
All |
Child, Adult, Older Adult |
NCT03225872 |
1604M86750 |
BOOST |
January 3, 2017 |
December 2050 |
December 2050 |
July 21, 2017 |
July 25, 2017 |
|
- Masonic Cancer Center
Minneapolis, Minnesota, United States
|
|
| 24 |
NCT02498808 |
Recruiting |
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases? |
|
|
Observational
|
|
- University of Oxford
- Arthritis Research UK
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Expression of IFNLR1/IL28Ra in human neutrophils, by laboratory measurement of blood neutrophils
- Vasculitis disease activity, based on a scale of disease activity in vasculitis (Birmingham Vasculitis Activity Score version 3.0, BVAS 3.0)
- Vasculitis damage, based on a scale of disease damage in vasculitis (Vasculitis Damage Index version 1.0, VDI 1.0)
- (and 3 more...)
|
85 |
All |
18 Years and older (Adult, Older Adult) |
NCT02498808 |
20892 |
ILAND |
September 2015 |
August 2018 |
December 2018 |
July 15, 2015 |
August 2, 2017 |
|
- Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
|
|
| 25 |
NCT02940015 |
Not yet recruiting |
Collection of Biological and Environmental Samples and Clinical Data From Anonymous Adult Men and Women for Quality Control and Methods Development and Evaluation (ASCA) |
|
|
Observational
|
|
- National Institute of Environmental Health Sciences (NIEHS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Other
- Time Perspective: Cross-Sectional
|
- The samples and clinical data will be used to ascertain whether data and sample collection, processing techniques, and testing methods are sufficiently valid and precise to be used in specific epidemiologic studies.
|
5000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02940015 |
170003
17-E-0003 |
|
October 19, 2016 |
June 1, 2026 |
June 1, 2026 |
October 20, 2016 |
August 9, 2018 |
|
- NIEHS Clinical Research Unit (CRU)
Research Triangle Park, North Carolina, United States
|
|
| 26 |
NCT01109394 |
Recruiting |
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies |
- Sarcoma
- Endocrine Tumors
- Neuroblastoma
- (and 2 more...)
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
|
6035 |
All |
up to 99 Years (Child, Adult, Older Adult) |
NCT01109394 |
100086
10-C-0086 |
|
April 19, 2010 |
|
|
April 23, 2010 |
December 12, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 27 |
NCT02867033 |
Recruiting |
National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES) |
|
- Procedure: biopsy
- Other: biobank constitution
- Procedure: Coloscopy
- (and 3 more...)
|
Interventional
|
Not Applicable |
- Centre Oscar Lambret
- Ligue contre le cancer, France
- Institut Curie
- Hôpital de la Timone
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Incident cases of aggressive fibromatosis
- Number of Aggressive Fibromatosis associated with familial adenomatous polyposis
- Percentage of CTNNB1 mutation in non-selected cases of Aggressive Fibromatosis
- (and 3 more...)
|
600 |
All |
Child, Adult, Older Adult |
NCT02867033 |
ALTITUDES-1508 |
ALTITUDES |
March 2016 |
February 2022 |
August 2022 |
August 15, 2016 |
July 12, 2018 |
|
- Centre Hospitalier Universitaire
Angers, France - Institut de Cancérologie de l'Ouest - Paul Papin
Angers, France - CHU de Besançon
Besancon, France - (and 36 more...)
|
|
| 28 |
NCT01459484 |
Recruiting |
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma |
|
- Drug: Mifamurtide arm
- Other: 3 drugs arm
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Events free survival in patient with ABCB1/P-glycoprotein over-expression, and who do not over-express ABCB1/P-glycoprotein
|
225 |
All |
up to 40 Years (Child, Adult) |
NCT01459484 |
ISG/OS-2
2011-001659-36 |
ISG/OS-2 |
July 2011 |
January 2020 |
February 2020 |
October 25, 2011 |
April 11, 2018 |
|
- I.R.C.C. - Unit of Medical Oncology
Candiolo, Torino, Italy - Presidio Sanitario Gradenigo
Torino, TO, Italy - Istituto Ortopedico Rizzoli
Bologna, Italy - (and 9 more...)
|
|
| 29 |
NCT03462888 |
Recruiting |
Clinico-biological Study/Characterization of Rhabdomyosarcoma in Adolescents and Young Adults, 15-25-year-old Patients |
|
|
Observational
|
|
- Centre Oscar Lambret
- Centre Leon Berard
- Société Française de lutte contre les Cancers et les leucémies de l’Enfant et l’adolescent
- (and 2 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Progression-free survival
- Clinical parameters of RMS in AYA
- Biological parameters of RMS in AYA
- (and 2 more...)
|
150 |
All |
15 Years to 25 Years (Child, Adult) |
NCT03462888 |
RMS-AJA-1701 |
RMS-AJA-1701 |
February 23, 2018 |
September 2018 |
September 2018 |
March 13, 2018 |
April 4, 2018 |
|
- Centre Oscar Lambret
Lille, France - CHU de Nancy
Nancy, France - Centre de Lacassagne à
Nice, France - Institut Claudius Regaud
Toulouse, France
|
|
| 30 |
NCT03496402 |
Recruiting |
Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) |
- Neuroblastoma
- Rhabdomyosarcoma
- Ewing Sarcoma Family of Tumors
- (and 3 more...)
|
- Other: Sampling on blood, bone marrow and cerebrospinal fluid
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number of patients with meaningful molecular genetic alterations
- Number of patients with meaningful immunological features
- Number of patients with identification of new tumor-specific genetic characteristics during follow-up (clonal evolution)
- (and 3 more...)
|
600 |
All |
1 Year to 25 Years (Child, Adult) |
NCT03496402 |
IC 2017-02 |
MICCHADO |
April 20, 2018 |
April 1, 2025 |
April 1, 2026 |
April 12, 2018 |
April 24, 2018 |
|
- Chu D'Amiens Picardie
Amiens, France - CHU Angers
Angers, France - CHRU de Besançon - Hôpital Jean-Minjoz
Besançon, France - (and 27 more...)
|
|
| 31 |
NCT01399281 |
Recruiting |
Pharmacovigilance in Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents and/or Methotrexate |
- Juvenile Idiopathic Arthritis
|
|
Observational
|
|
- Istituto Giannina Gaslini
- Members of the PRINTO network (PRINTO at www.printo.it)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Safety in patients with JIA on biologics/MTX from 3 to 10 years from drug initiation
- Long-term efficacy in patients with JIA on biologics/MTX from 3 to 10 years from drug initiation
- Predictors of safety from 3 to 10 years from drug initiation
- (and 5 more...)
|
9000 |
All |
6 Months to 30 Years (Child, Adult) |
NCT01399281 |
EU 260353 |
PharmaChild |
December 2011 |
December 2021 |
December 2021 |
July 21, 2011 |
March 5, 2018 |
|
- IRCCS G. Gaslini
Genoa, Italy
|
|
| 32 |
NCT01543594 |
Recruiting |
Italian Registry of Arthritis on Biologic Therapy |
|
|
Observational
|
|
- Gruppo Italiano Studio Early Arthritis
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
10000 |
All |
14 Years to 80 Years (Child, Adult, Older Adult) |
NCT01543594 |
DG-624
2012 |
GISEA |
January 2009 |
May 2020 |
December 2025 |
March 5, 2012 |
March 20, 2018 |
|
|
|
| 33 |
NCT01602302 |
Recruiting |
Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis |
|
- Drug: bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)
|
Interventional
|
Phase 4 |
- Medical University of Graz
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PD-signals predict relapse at week 16
- PD-signals predict relapse at week 24
- PD-signals predict relapse at week 52
- (and 8 more...)
|
110 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT01602302 |
2011-5; V2
2011-005204-15 |
RA-BioStop |
June 2012 |
July 2019 |
September 2019 |
May 18, 2012 |
August 21, 2018 |
|
- Medical University Graz
Graz, Austria
|
|
| 34 |
NCT03147352 |
Recruiting |
Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study |
- Necrotizing Soft Tissue Infection
- Necrotizing Fascitis
- Gas Gangrene
- Fournier Gangrene
|
- Device: Hyperbaric oxygen therapy
|
Observational
|
|
- Ole Hyldegaard
- Seventh Framework Programme
- Rigshospitalet, Denmark
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- sTM and sE-selectin as biomarkers of HBOT effect in NSTI patients
- suPAR as a biomarker of disease severity and prognosis in NSTI patients with and without septic shock
- Mortality
- (and 12 more...)
|
310 |
All |
18 Years and older (Adult, Older Adult) |
NCT03147352 |
PROTREAT1-PP-2017 |
ProTreat |
February 2013 |
January 2018 |
January 2018 |
May 10, 2017 |
May 10, 2017 |
|
- Copenhagen University Hospital, Rigshospitalet
Copenhagen, Denmark
|
|
| 35 |
NCT01587300 |
Recruiting |
Neuroblastoma Biology Study |
|
|
Observational
|
|
- New Approaches to Neuroblastoma Therapy Consortium
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
|
500 |
All |
up to 99 Years (Child, Adult, Older Adult) |
NCT01587300 |
N2004-05 |
|
July 2011 |
December 2018 |
June 2019 |
April 30, 2012 |
January 19, 2018 |
|
- Children's Hospital Los Angeles
Los Angeles, California, United States - Lucille Salter Packer Children's Hospital, Stanford University
Palo Alto, California, United States - UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States - (and 11 more...)
|
|
| 36 |
NCT03676868 |
Recruiting |
Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations |
- Cerebral Arteriovenous Malformations
- Ruptured or Unruptured Cerebral Arteriovenous Malformations
|
|
Observational
|
|
- Fondation Ophtalmologique Adolphe de Rothschild
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic
- Associaton between dosage of platelet and the arteriovenous malformation pronostic
- Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic
- Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT03676868 |
JDS_2018_6 |
BioMAV |
November 20, 2018 |
October 2028 |
October 2034 |
September 19, 2018 |
January 14, 2019 |
|
- Fondation Ophtalmologique Rotschild
Paris, France
|
|
| 37 |
NCT02176967 |
Recruiting |
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma |
- Ganglioneuroblastoma
- Localized Resectable Neuroblastoma
- Localized Unresectable Neuroblastoma
- (and 2 more...)
|
- Drug: Carboplatin
- Other: Clinical Observation
- Drug: Cyclophosphamide
- (and 4 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS) (Strata 1-4)
- Event-free survival (EFS)
- Time to intervention or tumor progression
- (and 8 more...)
|
621 |
All |
up to 17 Months (Child) |
NCT02176967 |
ANBL1232
NCI-2014-00677
s15-00462
U10CA180886
U10CA098543 |
|
July 28, 2014 |
June 30, 2026 |
|
June 27, 2014 |
August 7, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 210 more...)
|
|
| 38 |
NCT03534635 |
Recruiting |
Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) |
- Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting
|
- Drug: Pembrolizumab
- Drug: Pembrolizumab - additional treatment
|
Interventional
|
Phase 2 |
- Centre Hospitalier Universitaire Vaudois
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Identification of biomarkers using genomics and proteomics tools (single cell RNA analysis, exome sequencing, single cell profiling), multiplexed immunohistochemistry and bioinformatics.
- Efficacy, in order to define responder and non-responder patients and select translational findings that are associated to clinical outcome.
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03534635 |
CHUV-DO-PEMSYS_2017 |
|
June 1, 2018 |
June 1, 2026 |
June 1, 2026 |
May 23, 2018 |
August 31, 2018 |
|
- Olivier Michielin
Lausanne, Switzerland
|
|
| 39 |
NCT02111057 |
Recruiting |
Perioperative Flare in RA: Characterization of Clinical and Biological Features |
|
|
Observational
|
|
- Hospital for Special Surgery, New York
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rate of RA Flare at 6 week post surgery
- Severity and impact of flares 6 weeks and one year post arthroplasty, using the OMERACT PFQs
|
200 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02111057 |
2014-233 |
|
September 2013 |
December 2017 |
January 2018 |
April 10, 2014 |
March 15, 2017 |
|
- Hospital for Special Surgery
New York, New York, United States
|
|
| 40 |
NCT03737708 |
Recruiting |
A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA) |
- Rheumatoid Arthritis (RA)
|
- Drug: tacrolimus
- Drug: methotrexate
- Biological: adalimumab
- (and 2 more...)
|
Interventional
|
Phase 4 |
- Astellas Pharma Korea, Inc.
- Astellas Pharma Inc
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in disease activity score 28 (DAS28) erythrocyte sedimentation rate score (ESR) score at 12 weeks
- Disease activity score 28 (DAS28) erythrocyte sedimentation rate (ESR) rate score at 4 weeks
- DAS28 (ESR) score at 8 weeks
- (and 12 more...)
|
148 |
All |
19 Years to 75 Years (Adult, Older Adult) |
NCT03737708 |
506-MA-3187 |
|
November 14, 2018 |
February 2021 |
February 2021 |
November 9, 2018 |
January 11, 2019 |
|
- Site KR82004
Busan, Korea, Republic of - Site KR82003
Daegu, Korea, Republic of - Site KR82006
Daejeon, Korea, Republic of - (and 5 more...)
|
|
| 41 |
NCT02758769 |
Recruiting |
Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings |
|
- Biological: ORENCIA Subcutaneous Injection
|
Observational
|
|
- Bristol-Myers Squibb
- Ono Pharmaceutical Co. Ltd
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Percentage of achievement in simplified disease activity index (SDAI) remission after administration of abatacept
- Percentage of achievement in low disease activity by simplified disease activity index (SDAI).
- Change in the percentage of disease activity category by simplified disease activity index(SDAI)
- (and 19 more...)
|
300 |
All |
20 Years and older (Adult, Older Adult) |
NCT02758769 |
IM101-574 |
|
November 30, 2015 |
September 30, 2023 |
September 30, 2023 |
May 2, 2016 |
December 7, 2017 |
|
- Local Institution
Minato-ku, Tokyo, Japan
|
|
| 42 |
NCT03535402 |
Recruiting |
Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics |
|
|
Interventional
|
Phase 3 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Structural Efficacy of Sarilumab
- Clinical Response
- Compare Clinical and Structural Efficacy
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03535402 |
RA-012018 |
|
June 1, 2018 |
June 30, 2020 |
July 30, 2020 |
May 24, 2018 |
June 7, 2018 |
|
- AARDS Research, Inc
Aventura, Florida, United States
|
|
| 43 |
NCT03073109 |
Recruiting |
Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change from baseline in RAPID3 score at approximately month 6
- Change form baseline in adapted Health Assessment Questionnaire-Diseasbility Index (HAQ-DI) score at approximately month 6
- Change from baseline in Health Assessment Questionaire EQ-5D score at approximately month 6
- (and 2 more...)
|
320 |
All |
18 Years and older (Adult, Older Adult) |
NCT03073109 |
A3921284 |
|
March 15, 2017 |
August 1, 2019 |
August 1, 2019 |
March 8, 2017 |
February 6, 2019 |
|
- Artmedica
Medellin, Antioquia, Colombia - Hospital Pablo Tobon Uribe
Medellin, Antioquia, Colombia - Fundacion Instituto de Reumatologia Fernando Chalem
Bogota, Cundinamarca, Colombia - (and 12 more...)
|
|
| 44 |
NCT02714634 |
Not yet recruiting |
Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate |
- Rheumatoid Arthritis
- Insufficient Response to Methotrexate.
|
- Drug: Methotrexate + biologic administration
- Drug: methotrexate + salazopyrine + hydroxychloroquine administration
|
Interventional
|
Phase 4 |
- University Hospital, Strasbourg, France
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Numbers of participant with low disease activity (DAS28-CRP<3.2) and a daily dose ≤ 7.5 mg/day of equivalent prednisone
- Serious adverse events rate
- Blood concentrations of hydroxychloroquine, salazopyrine and methotrexate in the triple therapy group and methotrexate, biologic and anti-drug antibody in the other group.
- (and 10 more...)
|
286 |
All |
18 Years and older (Adult, Older Adult) |
NCT02714634 |
6020 |
BIO 3 |
March 2016 |
February 2020 |
February 2020 |
March 21, 2016 |
March 21, 2016 |
|
|
|
| 45 |
NCT03086343 |
Recruiting |
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE ) |
- Rheumatoid Arthritis (RA)
|
- Drug: Upadacitinib matching placebo
- Drug: Abatacept matching placebo
- Drug: Upadacitinib
- Drug: Abatacept
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) (non-inferiority)
- Proportion of participants achieving Disease Activity Score (DAS) 28 based Clinical Remission (CR)
- Change in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) (superiority)
|
550 |
All |
18 Years and older (Adult, Older Adult) |
NCT03086343 |
M15-925
2016-000933-37 |
SELECT-CHOICE |
May 9, 2017 |
February 29, 2020 |
June 7, 2022 |
March 22, 2017 |
February 11, 2019 |
|
- SunValley Arthritis Center, Lt /ID# 154558
Peoria, Arizona, United States - AZ Arthritis & Rheum Research /ID# 156539
Sun City, Arizona, United States - AZ Arth & Rheum Res /ID# 167161
Tucson, Arizona, United States - (and 159 more...)
|
|
| 46 |
NCT03793660 |
Recruiting |
Biologic National Registry |
- Arthritis, Rheumatoid
- Spondylitis
|
|
Observational
|
|
- Dacima Consulting
- Ligue Tunisienne Anti Rhumatismale
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Safety assessment of biotherapy - Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Occurrence of infection or tuberculosis or death or neoplasia or any other treatment-related side effect of biotherapy
- Assessment of Rheumatoid Arthritis Activity
- Health Assessment Questionnaire
- (and 3 more...)
|
600 |
All |
18 Years and older (Adult, Older Adult) |
NCT03793660 |
DAC-004-LITAR |
BINAR |
May 23, 2018 |
May 23, 2019 |
May 23, 2021 |
January 4, 2019 |
January 18, 2019 |
|
- Rheumatology Department - Habib Thameur
Ben Arous, Tunisia - Rheumatology Department - HMPIT
Ben Arous, Tunisia - Rheumatology Department - Tahar Sfar
Mahdia, Tunisia - (and 7 more...)
|
|
| 47 |
NCT01965132 |
Recruiting |
Korean College of Rheumatology Biologics Registry |
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
|
|
Observational
|
|
- Seoul National University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of participants with adverse events during the use of biologics in Korean patients with Rheumatic diseases
|
3500 |
All |
18 Years and older (Adult, Older Adult) |
NCT01965132 |
KOBIO_1 |
KOBIO |
January 1, 2013 |
December 31, 2022 |
June 30, 2023 |
October 18, 2013 |
June 6, 2018 |
|
- SMG-SNU Boramae Medical Center
Seoul, Korea, Republic of
|
|
| 48 |
NCT03610906 |
Recruiting |
Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy |
|
- Procedure: Tumor and Blood Specimens
|
Observational
|
|
- University of Colorado, Denver
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Identification of Potential Therapeutic Targets
- Survival
- Progression Free Survival (PFS)
- (and 2 more...)
|
250 |
All |
up to 21 Years (Child, Adult) |
NCT03610906 |
14-0426.cc |
|
April 7, 2014 |
December 2024 |
December 2024 |
August 1, 2018 |
August 1, 2018 |
|
- Children's Hospital Colorado
Aurora, Colorado, United States
|
|
| 49 |
NCT03364504 |
Not yet recruiting |
Biological Collection of Kidney Cells |
|
|
Interventional
|
Not Applicable |
- University Hospital, Angers
- Université de Nantes
- Hungarian Academy of Sciences
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Urine collection
- Isolation and culture of renal cells
- Impact of ABCC6 mutations on renal cell functions
- High throughput screening of drugs to restore ABCC6 function in PXE patients renal cells
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT03364504 |
49RC17_0063 |
CRHiPS |
January 2018 |
August 2018 |
December 2018 |
December 6, 2017 |
December 6, 2017 |
|
|
|
| 50 |
NCT02941302 |
Recruiting |
Multimodality Imaging Combined With Multiple Targets Pathological Examination for Detecting of Biological Borders of Gliomas: a Clinical Application Study |
|
- Procedure: Detecting of Biological Borders of Gliomas
|
Interventional
|
Not Applicable |
- General Hospital of Ningxia Medical University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- the biological border zone of glioma
- the degree of surgical resection of gliomas
|
50 |
All |
Child, Adult, Older Adult |
NCT02941302 |
xhechun3 |
|
October 1, 2016 |
October 31, 2018 |
December 31, 2018 |
October 21, 2016 |
November 28, 2017 |
|
- General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
|
|
| 51 |
NCT02233049 |
Recruiting |
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication |
- Diffuse Intrinsic Pontine Glioma
|
- Drug: Erlotinib
- Drug: Everolimus
- Drug: Dasatinib
|
Interventional
|
Phase 2 |
- Gustave Roussy, Cancer Campus, Grand Paris
- Innovative Therapies For Children with Cancer Consortium
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
250 |
All |
6 Months to 25 Years (Child, Adult) |
NCT02233049 |
2014-001929-32
2014/2126 |
BIOMEDE |
October 2014 |
October 2018 |
October 2018 |
September 8, 2014 |
July 23, 2018 |
|
- Gustave Roussy
Villejuif, Val De Marne, France
|
|
| 52 |
NCT02402244 |
Recruiting |
Project: Every Child for Younger Patients With Cancer |
- Central Nervous System Neoplasm
- Childhood Immature Teratoma
- Childhood Langerhans Cell Histiocytosis
- (and 7 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Medical Chart Review
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
|
- Preservation of clinically annotated, adequately preserved biological specimens for future research efforts
|
33000 |
All |
up to 25 Years (Child, Adult) |
NCT02402244 |
APEC14B1
NCI-2014-02057
U10CA098543 |
|
October 26, 2015 |
December 14, 2020 |
|
March 30, 2015 |
August 7, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 221 more...)
|
|
| 53 |
NCT03104374 |
Recruiting |
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug |
|
- Drug: Placebo
- Drug: ABT-494
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of participants achieving American College of Rheumatology (ACR) 20 response
- ACR 50 response
- Proportion of participants achieving a static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at least a 2-point improvement from baseline
- (and 8 more...)
|
630 |
All |
18 Years and older (Adult, Older Adult) |
NCT03104374 |
M15-554
2016-004152-30 |
SELECT - PsA 2 |
April 17, 2017 |
August 21, 2019 |
February 26, 2022 |
April 7, 2017 |
January 17, 2019 |
|
- Alabama Medical Group, PC /ID# 159836
Mobile, Alabama, United States - AZ Arthritis & Rheum Research /ID# 160047
Mesa, Arizona, United States - SunValley Arthritis Center, Lt /ID# 161203
Peoria, Arizona, United States - (and 163 more...)
|
|
| 54 |
NCT02823860 |
Recruiting |
Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies |
- Digestive Peritoneal Carcinomatosis
|
- Other: Collection of biospecimens and Quality of Life (QoL) assessment
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Resistance to oncological treatments
- Presence of biological and tumoral factors related to resistance to oncological treatments
- Presence of clinical factors related to resistance to oncological treatments.
- (and 7 more...)
|
15000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02823860 |
69HCL14_0345 |
BIG-RENAPE |
February 2016 |
February 2022 |
February 2022 |
July 6, 2016 |
April 26, 2017 |
|
- Centre Hospitalier Lyon Sud
Pierre Bénite, France
|
|
| 55 |
NCT02686229 |
Recruiting |
Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas |
|
|
Observational
|
|
- University of Ulm
- Institute for Epidemiology and Medical Biometrics, University of Ulm
- Charite University, Berlin, Germany
- Department of Internal Medicine III, University of Ulm
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progression-free survival (PFS)
- Overall survival (OS)
- Extent of tumor resection
- Quality of life (QoL) assessed by the EORTC QLQ C-30/BN-20. (European Organisation for Research and Treatment of Cancer Quality of Life Questionaire C-30
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT02686229 |
LoG-Glio |
LoG-Glio |
December 2015 |
December 2020 |
December 2030 |
February 19, 2016 |
March 11, 2016 |
|
- University of Ulm
Ulm, Germany
|
|
| 56 |
NCT03449264 |
Recruiting |
Development of Clinical and Biological Database |
- Digestive Cancer
- Gynecologic Cancer
- Breast Cancer
- Sarcoma
|
- Biological: biological collection
|
Interventional
|
Not Applicable |
- Institut du Cancer de Montpellier - Val d'Aurelle
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Proportion of patients who consent to participate in the study
|
2850 |
All |
18 Years and older (Adult, Older Adult) |
NCT03449264 |
ICM-URC2017/37 |
BCBInstitut |
July 27, 2017 |
August 2020 |
August 2020 |
February 28, 2018 |
February 28, 2018 |
|
- Institut regional du Cancer - Val d Aurelle
Montpellier, France
|
|
| 57 |
NCT00898365 |
Recruiting |
Study of Kidney Tumors in Younger Patients |
- Clear Cell Sarcoma of the Kidney
- Congenital Mesoblastic Nephroma
- Diffuse Hyperplastic Perilobar Nephroblastomatosis
- (and 10 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Disease-free survival
- Overall survival
- Loss of heterozygosity (LOH testing discontinued as of April 2014)
|
5000 |
All |
up to 29 Years (Child, Adult) |
NCT00898365 |
AREN03B2
NCI-2009-00416
CDR0000459797
COG-AREN03B2
U10CA180886
U10CA098543
UG1CA189958 |
|
February 27, 2006 |
January 1, 2100 |
|
May 12, 2009 |
August 7, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - (and 245 more...)
|
|
| 58 |
NCT03453619 |
Recruiting |
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies |
- IgA Nephropathy
- Lupus Nephritis
- Membranous Nephropathy
- (and 2 more...)
|
|
Interventional
|
Phase 2 |
- Apellis Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT03453619 |
APL2-201 |
|
January 22, 2018 |
December 22, 2019 |
June 22, 2020 |
March 5, 2018 |
January 15, 2019 |
|
- Apellis Investigational Site
Stanford, California, United States - Apellis Investigational Site
Aurora, Colorado, United States - Apellis Investigational Site
Denver, Colorado, United States - (and 14 more...)
|
|
| 59 |
NCT02272595 |
Recruiting |
Rational Therapeutics Based on Matched Tumor and Normal Tissue |
|
- Other: Treatment Based on Genetic Mutation
- Other: Treatment Based on No Genetic Mutation
|
Observational
|
|
- M.D. Anderson Cancer Center
- European Commission
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Progression-Free Survival (PFS)
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT02272595 |
PA12-0381 |
|
November 2014 |
November 2019 |
November 2020 |
October 23, 2014 |
January 24, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States - Cancer Institute Gustave Roussy
Villejuif, France - Chaim Sheba Medical Center at Tel Hasomer
Ramat Gan, Israel - Vall D'Hebron University Hospital
Barcelona, Spain
|
|
| 60 |
NCT02840175 |
Recruiting |
Treatment Tapering in JIA With Inactive Disease |
- Juvenile Idiopathic Arthritis
|
- Drug: etanercept
- Drug: adalimumab
- Drug: Abatacept
- Drug: Tocilizumab
|
Interventional
|
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Persistence of inactive disease
- Adverse and serious adverse events or of special interest
- Persistent inactive disease as defined by Wallace criteria
- (and 10 more...)
|
230 |
All |
2 Years to 17 Years (Child) |
NCT02840175 |
P 150902
2016-000312-15 |
AJIBIOREM |
May 18, 2017 |
November 2019 |
May 2021 |
July 21, 2016 |
May 16, 2018 |
|
- Necker Children's Hospital
Paris, France
|
|
| 61 |
NCT03016260 |
Recruiting |
RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis |
|
- Biological: Infliximab
- Biological: Adalimumab
- Biological: Etanercept
- (and 4 more...)
|
Observational
|
|
- TcLand Expression S.A.
- European Commission
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- EULAR response criteria
- ACR response criteria
- SDAI (Simplified Disease Activity Index) score
|
720 |
All |
18 Years and older (Adult, Older Adult) |
NCT03016260 |
2016-A00556-45 |
RABIOPRED |
December 2016 |
May 2018 |
December 2018 |
January 10, 2017 |
October 25, 2017 |
|
- Institute of Rheumatology
Prague, Czechia - CHU-Montpellier
Montpellier, France - CHU Nice
Nice, France - (and 5 more...)
|
|
| 62 |
NCT03277703 |
Recruiting |
Flu Vaccine Response in Patients on Biologic Therapies |
- Rheumatologic Disorder
- Inflammatory Bowel Diseases
- Immune Complex Diseases
|
- Biological: Influenza vaccine
|
Interventional
|
Phase 2 |
- Stony Brook University
- University of North Carolina, Chapel Hill
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Influenza hemagglutination inhibition (HAI) titer
- Clinical efficacy of vaccine
|
54 |
All |
3 Years to 22 Years (Child, Adult) |
NCT03277703 |
1077651 |
|
November 3, 2017 |
April 2020 |
August 2020 |
September 11, 2017 |
September 7, 2018 |
|
- Clinical Research Center
East Setauket, New York, United States
|
|
| 63 |
NCT03178955 |
Recruiting |
Circadian RA Study in Rheumatoid Arthritis Subjects |
|
|
Observational
|
|
- University of California, Davis
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- change in pseudo F-statistic
- change in acrophase
- change in mesor
- (and 7 more...)
|
30 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03178955 |
1023265 |
|
March 27, 2017 |
June 30, 2019 |
June 30, 2019 |
June 7, 2017 |
January 15, 2019 |
|
- UC Davis Center for Musculoskeletal Health
Sacramento, California, United States
|
|
| 64 |
NCT00004847 |
Recruiting |
Diagnosis of Pheochromocytoma |
- Pheochromocytoma
- Endocrine Disease
- Endocrine Diseases
|
- Drug: Fluorodopamine
- Drug: F-18 Fluorodopa
|
Interventional
|
Phase 1 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To study specific genotypes, biochemical and imaging phenotypes of patients with various pheochromocytomas and paragangliomas.
|
2400 |
All |
up to 150 Years (Child, Adult, Older Adult) |
NCT00004847 |
000093
00-CH-0093 |
|
March 1, 2000 |
November 30, 2048 |
November 30, 2048 |
March 3, 2000 |
January 29, 2019 |
|
- Johns Hopkins University
Baltimore, Maryland, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 65 |
NCT03755466 |
Recruiting |
Examination of Efficacy and Safety of Baricitinib in RA Patients |
|
- Drug: "Baricitinib", "olumiant®"
- Drug: "Biologics"
- Drug: Tofacitinib 5 MG [Xeljanz]
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Assessment of Disease Activity in rheumatoid patients for 1 year treated by baricitinib (N=30), biologics (N=30), or tofacitinib (N=30). Also, the efficacy and adverse event of each drug for 1 year in the RA patients.
|
90 |
All |
20 Years and older (Adult, Older Adult) |
NCT03755466 |
BARI2018 |
|
November 21, 2018 |
November 20, 2019 |
November 20, 2023 |
November 28, 2018 |
December 3, 2018 |
|
- Yukio Nakamura
Matsumoto, Nagano, Japan
|
|
| 66 |
NCT02540044 |
Recruiting |
Supporting Patient Care With Electronic Resource (SuPER) |
|
- Behavioral: ANSWER-2 decision aid
- Behavioral: Control Group (TAS Consumer Guide)
|
Interventional
|
Not Applicable |
- University of British Columbia
- University of Alberta
- Simon Fraser University
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Decisional Conflict Scale
- MeiQ
- Partners in Health Scale
- Health Resource Utilization
|
148 |
All |
19 Years and older (Adult, Older Adult) |
NCT02540044 |
H15-02046 |
SuPER |
January 2016 |
December 2018 |
December 2018 |
September 3, 2015 |
June 29, 2017 |
|
- Arthritis Research Canada
Richmond, British Columbia, Canada
|
|
| 67 |
NCT03082573 |
Recruiting |
Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel |
|
|
Interventional
|
Phase 4 |
- Iraj Sabahi Research Inc.
- Mallinckrodt
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- ACR 20 response ACR 20 response
- ACR 50 response
- ACR 70 response
- (and 7 more...)
|
30 |
All |
21 Years and older (Adult, Older Adult) |
NCT03082573 |
IS2017 |
|
March 3, 2017 |
February 2018 |
February 2019 |
March 17, 2017 |
March 17, 2017 |
|
- Iraj Sabahi Research Inc
Pleasanton, California, United States - Iraj Sabahi Research Inc
Turlock, California, United States
|
|
| 68 |
NCT03700021 |
Not yet recruiting |
Response to Treatment With Intravenous Abatacept Adults With Rheumatoid Arthritis |
|
- Drug: Abatacept + csDMARD
|
Interventional
|
Phase 4 |
- New York University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Activity measured using Health Assessment Questionnaire (HAQ)
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT03700021 |
18-01164 |
|
April 2019 |
November 2019 |
November 2019 |
October 9, 2018 |
January 25, 2019 |
|
- New York University Langone Health
New York, New York, United States
|
|
| 69 |
NCT03682705 |
Recruiting |
A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis. |
- Rheumatoid Arthritis (RA)
|
- Drug: Updacitinib
- Drug: ABBV-105
- Drug: Upadacitinib placebo
- Drug: ABBV-105 placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Disease Activity Score (DAS) 28 (C-reactive protein [CRP])
- Change from baseline in Clinical Disease Activity Index (CDAI)
- Proportion of participants achieving Clinical Remission (CR)
- (and 13 more...)
|
240 |
All |
18 Years and older (Adult, Older Adult) |
NCT03682705 |
M16-063
2018-000666-10 |
|
October 8, 2018 |
November 17, 2019 |
January 15, 2020 |
September 25, 2018 |
February 7, 2019 |
|
- Rheum Assoc of North Alabama /ID# 167382
Huntsville, Alabama, United States - AZ Arthritis & Rheum Research /ID# 167446
Mesa, Arizona, United States - AZ Arthritis and Rheum Researc /ID# 167448
Phoenix, Arizona, United States - (and 113 more...)
|
|
| 70 |
NCT02066220 |
Recruiting |
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma |
|
- Radiation: Radiotherapy without Carboplatin
- Drug: Reduced-intensity maintenance chemotherapy
- Radiation: Radiotherapy with Carboplatin
- Drug: Maintenance chemotherapy
|
Interventional
|
Phase 2
Phase 3 |
- Universitätsklinikum Hamburg-Eppendorf
- Deutsche Kinderkrebsstiftung
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 3-year Event-Free Survival (EFS)
- Overall survival
- Pattern of relapse
- (and 8 more...)
|
360 |
All |
3 Years to 21 Years (Child, Adult) |
NCT02066220 |
SIOP PNET 5 MB
2011-004868-30 |
|
June 2014 |
April 2024 |
April 2024 |
February 19, 2014 |
May 8, 2017 |
|
- Medical University of Graz
Graz, Austria - University Hospital Gasthuisberg
Leuven, Belgium - University Hospital Brno
Brno, Czechia - (and 74 more...)
|
|
| 71 |
NCT02980198 |
Recruiting |
Study of IFN-K in Dermatomyositis |
|
- Biological: IFN-Kinoid
- Other: Placebo
- Other: ISA 51
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Change from baseline in the expression of IFN-induced genes at Week 48
- Number of subjects with treatment related adverse events
- Total improvement score from IMAC Core Set Measures (CSM) following Aggarwal et al (2017) recommendations
- (and 5 more...)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02980198 |
IFN-K-005-DM
2016-000137-52 |
|
November 2016 |
December 2018 |
|
December 2, 2016 |
September 11, 2017 |
|
- Research site
Lille, France - Research site
Marseille, France - Research site
Paris, France - (and 5 more...)
|
|
| 72 |
NCT02286167 |
Recruiting |
Glioma Modified Atkins-based Diet in Patients With Glioblastoma |
|
|
Interventional
|
Not Applicable |
- Wake Forest University Health Sciences
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Feasibility of intermittent modified Atkins diet in patients with GBM assessed by percent of patients able to remain on the diet and achieve nutritional goals
- Biologic activity measured by pre- and post-study cerebral glutamate and glutamine concentrations assessed by MRS.
- Tolerability assessed by percent of patients who have an adverse reaction of any grade attributed to the diet of possible, probable, or definite
- Dietary Activity
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT02286167 |
IRB00037347 |
GLAD |
November 2014 |
April 2019 |
April 2019 |
November 7, 2014 |
July 16, 2018 |
|
- The Johns Hopkins Hospital
Baltimore, Maryland, United States - Wake Forest School of Medicine
Winston-Salem, North Carolina, United States
|
|
| 73 |
NCT01445288 |
Recruiting |
Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors |
- Diffuse Intrinsic Pontine Glioma
- PNET
- Ependymoma
- (and 2 more...)
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Measure changes in antiogenesis, blood brain barrier permability and neurotoxicity re to radiation of the CNS
- Describe changes in imaging, endocrine function after xrt to the brain
- Monitor changes in serum proteome and germline polymorphisms
|
150 |
All |
up to 21 Years (Child, Adult) |
NCT01445288 |
060219
06-C-0219 |
|
August 1, 2006 |
|
|
October 3, 2011 |
February 11, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 74 |
NCT02828202 |
Recruiting |
Follow-up of a National Cohort of Melanoma Stage IV and Unresectable Stage III Patients |
|
- Other: Biological
- Other: Tissular
- Other: Quality of life
|
Observational
|
|
- Assistance Publique - Hôpitaux de Paris
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Overall survival
- Progression-Free Survival (PFS)
- Overall response
- Nature and incidence of Treatment-Emergent Adverse Events (Safety)
|
2000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02828202 |
ID-RCB 2015-A00138-41
2011-244 |
MelBase |
February 2013 |
March 2021 |
March 2021 |
July 11, 2016 |
February 15, 2019 |
|
- CHU d'Amiens
Amiens, France - CH Annecy Genevois
Annecy, France - CHU de Besançon
Besançon, France - (and 24 more...)
|
|
| 75 |
NCT03387592 |
Recruiting |
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas |
|
- Drug: CPT-11
- Drug: Calcio levofolinate
- Drug: 5-Fluorouracil
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- DCR
- Incidence of treament related adverse events
- OS
- (and 4 more...)
|
112 |
All |
18 Years and older (Adult, Older Adult) |
NCT03387592 |
IRST100.22 |
SENECA |
March 6, 2017 |
January 2021 |
January 2021 |
January 2, 2018 |
January 2, 2018 |
|
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
Meldola, FC, Italy - Istituto Nazionale Tumori Milano
Milano, MI, Italy - Azienda Ospedaliera-Universitaria di Modena
Modena, MO, Italy - (and 7 more...)
|
|
| 76 |
NCT00002663 |
Recruiting |
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies |
- EBV-induced Lymphomas
- EBV-associated Malignancies
- Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
|
- Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
|
Interventional
|
Phase 1
Phase 2 |
- Atara Biotherapeutics
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
|
Industry / Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy as defined by response rate
- In vivo expansion and duration of EBV-CTLs measured via CTLp assay over time (cells/mL/time)
- Durability of clinical responses (time)
|
84 |
All |
Child, Adult, Older Adult |
NCT00002663 |
95-024
P30CA008748
MSKCC-95024
NCI-V95-0685 |
|
March 1995 |
August 2019 |
August 2019 |
January 27, 2003 |
August 14, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
|
| 77 |
NCT02884362 |
Recruiting |
Prospective Melanoma Database |
|
- Other: clinical biological data collection on melanoma
|
Observational
|
|
|
Other |
- Time Perspective: Prospective
|
- Database of patients with melanoma
|
10000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02884362 |
16HLCUTA01 |
|
January 2016 |
January 2026 |
June 2026 |
August 31, 2016 |
August 31, 2016 |
|
- Institut claudius regaud IUCT ONCOPOLE
Toulouse, France
|
|
| 78 |
NCT02466217 |
Recruiting |
Phenomics in Autoimmune and Inflammatory Diseases |
- Healthy Volunteer
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- (and 10 more...)
|
- Other: 1: AID groups
- Other: 2: Control groups
|
Observational
|
|
- Assistance Publique - Hôpitaux de Paris
- National Research Agency, France
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Total peripheral blood gene expression between patients, expressed as fluorescence intensity
- Tregs and Tconvs T cell receptor repertoire, expressed as the % of unique TCR sequences
- HLA type and SNPs expressed as the occurrence events across patients
- (and 15 more...)
|
1300 |
All |
18 Years and older (Adult, Older Adult) |
NCT02466217 |
P141006
2015-A00558-41 |
TRANSIMMUNOM |
July 2015 |
July 2019 |
July 2021 |
June 9, 2015 |
December 13, 2016 |
|
- Rhumatologie - Hôpital Saint-Antoine
Paris, France - CIC Paris-Est, Hôpital PITIE SALPETRIERE
Paris, France
|
|
| 79 |
NCT03617939 |
Recruiting |
A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer |
|
- Procedure: Biospeciman Collection
- Other: Survey Assessments
- Other: Medical Chart Reviews
|
Observational
|
|
- University of Colorado, Denver
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Improve Standard of Cancer Care
|
10000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03617939 |
15-1110.cc |
|
September 16, 2015 |
September 2035 |
September 2037 |
August 7, 2018 |
January 16, 2019 |
|
- University of Colorado Hospital
Aurora, Colorado, United States - UCHealth Memorial Hospital
Colorado Springs, Colorado, United States
|
|
| 80 |
NCT00442195 |
Recruiting |
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers |
|
|
Observational
|
|
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Other
- Time Perspective: Prospective
|
- To obtain blood, bone marrow, and skin punch biopsy samples and/or buccal mucosa samples from subjects seeking to participate as healthy volunteers in NIH laboratory research studies.
|
99999999 |
All |
8 Years and older (Child, Adult, Older Adult) |
NCT00442195 |
070113
07-H-0113 |
|
February 27, 2007 |
|
|
March 1, 2007 |
February 15, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 81 |
NCT02775643 |
Recruiting |
Molecular Analysis of Childhood and Adolescent Melanocytic Lesions |
|
|
Observational
|
|
- St. Jude Children's Research Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Genomic profile
- Overall Survival (OS)
|
500 |
All |
up to 18 Years (Child, Adult) |
NCT02775643 |
MACMEL |
|
May 31, 2016 |
May 31, 2031 |
May 31, 2041 |
May 17, 2016 |
October 15, 2018 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
|
Create an RSS feed from your search for:
Download the search results for: